These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 8522960)

  • 1. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions.
    Gudelsky GA; Nash JF
    J Neurochem; 1996 Jan; 66(1):243-9. PubMed ID: 8522960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine.
    Shankaran M; Yamamoto BK; Gudelsky GA
    Eur J Pharmacol; 1999 Dec; 385(2-3):103-10. PubMed ID: 10607865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDMA induced dopamine release in vivo: role of endogenous serotonin.
    Koch S; Galloway MP
    J Neural Transm (Vienna); 1997; 104(2-3):135-46. PubMed ID: 9203077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of protein kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA) occurs through the stimulation of serotonin receptors and transporter.
    Kramer HK; Poblete JC; Azmitia EC
    Neuropsychopharmacology; 1997 Sep; 17(3):117-29. PubMed ID: 9272479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on striatal neurotoxicity caused by the 3,4-methylenedioxymethamphetamine/ malonate combination: implications for serotonin/dopamine interactions.
    Goñi-Allo B; Ramos M; Herv'as I; Lasheras B; Aguirre N
    J Psychopharmacol; 2006 Mar; 20(2):245-56. PubMed ID: 16510482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-Deoxy-D-glucose prevents and nicotinamide potentiates 3, 4-methylenedioxymethamphetamine-induced serotonin neurotoxicity.
    Hervías I; Lasheras B; Aguirre N
    J Neurochem; 2000 Sep; 75(3):982-90. PubMed ID: 10936179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum.
    Kanthasamy A; Sprague JE; Shotwell JR; Nichols DE
    Neuroscience; 2002; 114(4):917-24. PubMed ID: 12379247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats.
    Mechan AO; Esteban B; O'Shea E; Elliott JM; Colado MI; Green AR
    Br J Pharmacol; 2002 Jan; 135(1):170-80. PubMed ID: 11786492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevation of ambient room temperature has differential effects on MDMA-induced 5-HT and dopamine release in striatum and nucleus accumbens of rats.
    O'Shea E; Escobedo I; Orio L; Sanchez V; Navarro M; Green AR; Colado MI
    Neuropsychopharmacology; 2005 Jul; 30(7):1312-23. PubMed ID: 15688085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein kinase C inhibition differentially affects 3,4-methylenedioxymethamphetamine-induced dopamine release in the striatum and prefrontal cortex of the rat.
    Nair SG; Gudelsky GA
    Brain Res; 2004 Jul; 1013(2):168-73. PubMed ID: 15193525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain.
    Baumann MH; Clark RD; Rothman RB
    Pharmacol Biochem Behav; 2008 Aug; 90(2):208-17. PubMed ID: 18403002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous 5-HT, released by MDMA through serotonin transporter- and secretory vesicle-dependent mechanisms, reduces hippocampal excitatory synaptic transmission by preferential activation of 5-HT1B receptors located on CA1 pyramidal neurons.
    Mlinar B; Corradetti R
    Eur J Neurosci; 2003 Sep; 18(6):1559-71. PubMed ID: 14511335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ethanol and 3,4-methylenedioxymethamphetamine (MDMA) alone or in combination on spontaneous and evoked overflow of dopamine, serotonin and acetylcholine in striatal slices of the rat brain.
    Riegert C; Wedekind F; Hamida SB; Rutz S; Rothmaier AK; Jones BC; Cassel JC; Jackisch R
    Int J Neuropsychopharmacol; 2008 Sep; 11(6):743-63. PubMed ID: 18248690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra.
    Yamamoto BK; Nash JF; Gudelsky GA
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1063-70. PubMed ID: 7791076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate.
    Nixdorf WL; Burrows KB; Gudelsky GA; Yamamoto BK
    J Neurochem; 2001 Apr; 77(2):647-54. PubMed ID: 11299327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain.
    O'Shea E; Esteban B; Camarero J; Green AR; Colado MI
    Neuropharmacology; 2001; 40(1):65-74. PubMed ID: 11077072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic unpredictable stress augments +3,4-methylenedioxymethamphetamine-induced monoamine depletions: the role of corticosterone.
    Johnson BN; Yamamoto BK
    Neuroscience; 2009 Apr; 159(4):1233-43. PubMed ID: 19409219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in the in vivo dynamics of neurotransmitter release and serotonin uptake after acute para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine revealed by chronoamperometry.
    Callaghan PD; Irvine RJ; Daws LC
    Neurochem Int; 2005 Oct; 47(5):350-61. PubMed ID: 15979209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists.
    Gudelsky GA; Yamamoto BK; Nash JF
    Eur J Pharmacol; 1994 Nov; 264(3):325-30. PubMed ID: 7698172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonergic deficits and impaired passive-avoidance learning in rats by MDEA: a comparison with MDMA.
    Barrionuevo M; Aguirre N; Del Río JD; Lasheras B
    Pharmacol Biochem Behav; 2000 Feb; 65(2):233-40. PubMed ID: 10672974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.